We caught up with Naghmana Bajwa, MD, Global Medical Affairs Haematology Lead at Shire to find out the latest in haemophilia disease research…
What is haemophilia and how does it affect the body?
Haemophilia is an x-linked recessive congenitally inherited bleeding disorder, which means blood does not clot properly, due to absent or deficient clotting factors, proteins in the blood that control bleeding.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
There are two commonly known forms of haemophilia, A and B. Haemophilia A is more common than haemophilia B and is caused by a clotting factor VIII (factor 8) deficiency, haemophilia B is caused by a clotting factor IX (factor 9) deficiency. Both forms cause individuals to bleed longer than normal, and these bleeds can sometimes occur spontaneously. Bleeding episodes can occur in any part of the body but 70-75% of them occur in the joints.
Who is affected by the condition and what risks does it pose?
Since haemophilia is an inherited rare bleeding disorder, it often begins in infancy and is known to be more prevalent among males. In fact, this rare disorder affects about 1 in 5,000[1] new-born males and an estimated 400,000 people worldwide.[2]
The severity of haemophilia varies from person to person, and depends on the amount of clotting factor missing from their systems. Uncontrollable spontaneous bleeds can be fatal, especially if they occur in the brain or in vital organs.
Inhibitors are a rare but serious complication that forms when the body’s immune system attacks the molecules in factor therapy. An inhibitor neutralise the clotting factors and rendering the infused factor inactive resulting in hard to control bleeds leading to increased severity of the disease including fatalities. is a rare but serious complication that forms when the body’s immune system attacks the molecules in factor therapy. 30% of patients with haemophilia A and 20% of haemophilia B will develop inhibitors.
People with haemophilia especially patients with inhibitors can also experience joint deformities and arthritis. It’s a crippling disorder and can immensely impact an individual’s daily routine and quality of life. Given the course of haemophilia is unique in every individual, it is important that physicians have multiple treatment options to manage bleeds safely and effectively, particularly those that occur spontaneously.
What type of treatments are currently available? How do they work to treat the condition?
As haemophilia is caused by a deficiency of a blood coagulation factor, the global gold standard of care is factor replacement therapy, according to the Centers for Disease Control and Prevention (CDC), the World Federation of Haemophilia (WHF) and the National Haemophilia Foundation. Factor replacement therapies can be made from human blood (plasma-derived products) or genetically engineered cells that have human factor gene (recombinant products). They are infused intravenously by a physician or home therapy on a routine (prophylaxis) or as-needed (on-demand) basis.
Shire’s recombinant factor replacement product, ADVATE, is the most commonly prescribed factor replacement therapy for haemophilia A.
More recently, extended circulating half-life recombinant factor replacement therapies, such as ADYNOVI, have been made available to individuals with haemophilia. ADYNOVI is built on the safety and efficacy of ADVATE, but has a simpler and less frequent dosing schedule, helping to further individualise options for this patient population.
How can personalised medicine be used to treat haemophilia?
For decades, physicians developed haemophilia treatment dosing schedules with an approach based on a patient’s weight. This approach resulted in reasonable outcomes for many, but not all, patients.
Through research in recent years, we have learned that patient activity, lifestyle, as well as the likelihood of joint disease, are also important measures for tailoring treatment to individuals’ needs.
For example, Shire’s algorithm device, MyPKFiT helps physicians evaluate measures along with key health indicators like age and weight, to develop personalised dosing regimens. Personalised care in haemophilia is essential because every haemophilia patient is unique and processes factor therapy differently. Devices like MyPKFiT help physicians track and more precisely dose patients in a way that maintains optimal factor activity levels to manage bleeds effectively and safely. Shire is driving innovation with devices like MyPKFiT, which is the first and only registered medical device for haemophilia dosing, making personalisation possible in the real world.
Haemophilia with inhibitors is harder to control than without inhibitors. As haemophilia with inhibitors is caused by reduced or no response to infused factors; a by-passing agent that goes around the missing factors to stop bleeding is required. One such product is Shire’ by-passing agent APCC or FEIBA, which helps to bypass the inhibitor to help the body form a clot and stop bleeding.
About FEIBA
FEIBA contains a unique combination of coagulation factors, restoring haemostasis through multiple modes of action. Importantly, FEIBA provides Factor II and Factor Xa, which are major drivers in the development of the clot formation, as they produce thrombin downstream from the inhibitor blockade.
FEIBA has over 40 years of efficacy and safety data.
What is in Shire’s pipeline in terms of medication and treatment?
We are looking forward to beginning our clinical trial for our gene therapy haemophilia A and B treatment to evaluate an innovative approach to gene therapy for patients with haemophilia A and B. The studies will begin later this year, and will create an opportunity for patients to potentially lead bleed-free lives. We’re excited about the ongoing research in gene therapy, and building our pipeline product portfolio.
We are also looking forward to advancing patient care and research in other rare bleeding disorders like von Willebrand disease (vWD) and thrombotic thrombocytopenic purpura.
How is Shire ensuring factor based standards of care globally?
With heritage and experience in the space spanning more than 70 years and a broad portfolio, Shire is committed to increasing standard of care globally through focus on early diagnosis, early prophylaxis and personalisation to ensure the right treatments are available to patients.
Much of the work we do in terms of disease awareness involves educating physicians and healthcare providers throughout the world about the value of factor replacement therapies, and how they can be used in the most appropriate way.
Shire also has strong partnerships with key patient groups, such as the World Federation of Haemophilia, which overall has led to the diagnosis of approximately 30,000 patients globally. And, also the European haemophilia Consortium which represents approximately 90,000 people diagnosed with a rare bleeding conditions such as haemophilia, von Willebrand Disease (VWD) and other rare bleeding disorders across Europe.
Shire haematology portfolio
ADYNOVI™ is an innovative recombinant Factor VIII treatment designed to offer simple, twice-weekly dosing is built on ADVATE [Antihemophilic Factor (Recombinant)] using an established technology.
ADVATE® with myPkFit: used to replace clotting factor (factor VIII or antihemophilic factor) that is missing in people with hemophilia A (also called “classic” hemophilia). ADVATE® is used to prevent and control bleeding in adults and children (0-16 years) with hemophilia A; myPkFit is the first device for ADVATE® patients allowing the HCPs to personalize their dosing.
VONVENDI® [von Willebrand factor (Recombinant)] is an innovative recombinant protein treatment that includes a physiologic distribution of proteins called multimers, including ultra-large multimers (ULMs), with large multimers being the most active form of the protein supporting clot formation.
Obizur is the only recombinant porcine factor FVIII that temporarily replaces the inhibited endogenous factor VIII that is needed for effective bleeding control in patients with acquired hemophilia A (AHA). Acquired hemophilia is a disease where patients develop inhibitors to their clotting factors especially factor FVIII and IX. Obizur is being used in AHA and bypassing agents are used in AHB.
FEIBA (Anti-Inhibitor Coagulant Complex) is used for people with Hemophilia A or B with Inhibitors to control and prevent bleeding episodes, before surgery, or routinely to prevent or reduce the number of bleeding episodes.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.